Breaking News

Charles River Completes Acquisition of Galapagos’ CRO Services

April 1, 2014

Stay tuned for Contract Pharma's Newsmaker interview with CEO, James Foster

Charles River Laboratories (CRL) has completed the acquisition of the CRO services division of Galapagos NV, which includes both Argenta and BioFocus, for$179 million in cash. The acquisition, along with CRL’s current capabilities, adds integrated in vitro and in vivo capabilities from target discovery through preclinical development.
 
Argenta and BioFocus, located in the UK and the Netherlands, provide drug discovery services from target discovery through the delivery of clinic-ready candidates. Their in vitro expertise includes medicinal chemistry, target discovery, and complex in vitro biology, as well as therapeutic area expertise in respiratory, inflammation, oncology, and CNS diseases.
 
The acquisition is expected to add approximately 6% to Charles River’s sales in 2014.
 
For the May issue, be on the look out for Contract Pharma’s Newsmakers piece with Charles River's president and chief executive officer, James C. Foster! 

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important